Ye Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ye Cui has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Zhe Lv
Capital Medical University
9 shared publicationsXinqian Du
Capital Medical University
6 shared publicationsJie Liu
Capital Medical University
5 shared publicationsXinyu Zhang
Capital Medical University
5 shared publicationsYan Chen
Capital Medical University
5 shared publicationsYing Sun
Capital Medical University
5 shared publications
Latest Publications
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (5) , C1274-C1296
Lymphatic endothelial senescence is associated with drainage failure despite vessel expansion in pulmonary fibrosis
The lymphatic vasculature in fibrotic lungs expands morphologically yet fails functionally, revealing a fundamental dissociation between vessel density and drainage competence. Senescence-associated transcriptional reprogramming in lymphatic endothelial cells coincides with this transport failure and with suppression of key molecular signals governing macrophage egress, linking lymphatic dysfunction to sustained immune cell retention. Bidirectional lymphatic modulation in complementary fibrosis models identifies drainage competence as a decisive factor in disease outcome and a tractable therapeutic target.
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (5) , C1274-C1296
Lymphatic endothelial senescence is associated with drainage failure despite vessel expansion in pulmonary fibrosis
The lymphatic vasculature in fibrotic lungs expands morphologically yet fails functionally, revealing a fundamental dissociation between vessel density and drainage competence. Senescence-associated transcriptional reprogramming in lymphatic endothelial cells coincides with this transport failure and with suppression of key molecular signals governing macrophage egress, linking lymphatic dysfunction to sustained immune cell retention. Bidirectional lymphatic modulation in complementary fibrosis models identifies drainage competence as a decisive factor in disease outcome and a tractable therapeutic target.
- 29 May 2026
- Published by IOP Publishing in Biomedical Materials
- Vol. 21 (3) , 032006
Breathing life into fibrosis research: precision-cut lung slices, organoids, and organs-on-chip as transformative models
Pulmonary fibrosis represents one of the most challenging frontiers in respiratory medicine, characterized by progressive scarring that ultimately leads to respiratory failure and death. Despite decades of research, therapeutic options remain frustratingly limited, with only three Food and Drug Administration-approved agents that merely slow disease progression without reversing established fibrosis. This therapeutic impasse stems largely from the translational disconnect between traditional preclinical models and human disease complexity. Animal models fail to recapitulate the chronic, progressive nature of human fibrosis, while conventional cell culture systems cannot capture the intricate three-dimensional architecture and multicellular interactions that drive fibrotic remodeling. The emergence of new approach methodologies has catalyzed a paradigm shift in pulmonary fibrosis research, offering unprecedented opportunities to model human disease with greater fidelity. This review examines three revolutionary platforms that are reshaping our understanding of fibrotic mechanisms: precision-cut lung slices that preserve native tissue architecture, self-organizing lung organoids that enable patient-specific disease modeling, and microfluidic lung-on-chip systems that recreate physiological breathing mechanics. We critically evaluate the unique capabilities and inherent limitations of each technology, explore their applications in mechanistic studies and drug discovery, and discuss emerging hybrid approaches that promise to accelerate therapeutic development. By synthesizing current evidence and identifying future directions, this review provides a roadmap for leveraging these innovative technologies to finally break through the therapeutic ceiling in pulmonary fibrosis.
- 29 May 2026
- Published by IOP Publishing in Biomedical Materials
- Vol. 21 (3) , 032006
Breathing life into fibrosis research: precision-cut lung slices, organoids, and organs-on-chip as transformative models
Pulmonary fibrosis represents one of the most challenging frontiers in respiratory medicine, characterized by progressive scarring that ultimately leads to respiratory failure and death. Despite decades of research, therapeutic options remain frustratingly limited, with only three Food and Drug Administration-approved agents that merely slow disease progression without reversing established fibrosis. This therapeutic impasse stems largely from the translational disconnect between traditional preclinical models and human disease complexity. Animal models fail to recapitulate the chronic, progressive nature of human fibrosis, while conventional cell culture systems cannot capture the intricate three-dimensional architecture and multicellular interactions that drive fibrotic remodeling. The emergence of new approach methodologies has catalyzed a paradigm shift in pulmonary fibrosis research, offering unprecedented opportunities to model human disease with greater fidelity. This review examines three revolutionary platforms that are reshaping our understanding of fibrotic mechanisms: precision-cut lung slices that preserve native tissue architecture, self-organizing lung organoids that enable patient-specific disease modeling, and microfluidic lung-on-chip systems that recreate physiological breathing mechanics. We critically evaluate the unique capabilities and inherent limitations of each technology, explore their applications in mechanistic studies and drug discovery, and discuss emerging hybrid approaches that promise to accelerate therapeutic development. By synthesizing current evidence and identifying future directions, this review provides a roadmap for leveraging these innovative technologies to finally break through the therapeutic ceiling in pulmonary fibrosis.
- 20 February 2026
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 94, 127850
The metallic trinity: Understanding the roles and interplay of copper, zinc, and iron in pulmonary fibrosis – A comprehensive review
- 20 February 2026
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 94, 127850
The metallic trinity: Understanding the roles and interplay of copper, zinc, and iron in pulmonary fibrosis – A comprehensive review
- Open Access
- 13 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (22) , e09332
Single‐Cell RNA Sequencing of Human Lung Tissues Reveals Metallothionein‐Positive T Cells as a Novel Potential Marker of Susceptibility to Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous disease with complex pathogenesis. Identifying high‐risk populations and implementing timely prevention strategies are critical to reducing the disease burden. Single‐cell RNA sequencing of lung tissue from control never‐smokers, patients with pre‐COPD, and COPD patients revealed a novel T cell subset characterized by high expression of metallothionein (MT) genes, designated MT‐high T cells. These cells were progressively depleted in the lungs with disease progression. A similar decline was observed in the peripheral blood using flow cytometry, highlighting the potential of these cells to serve as an accessible biomarker of disease progression. Functional analysis indicated that MT‐high T cells suppress CD8 + T cell cytotoxic activity, suggesting a key immunoregulatory role in disease pathogenesis. Receiver operating characteristic curve analysis demonstrated the excellent potential of MT‐high T cell frequency to predict susceptibility to COPD. These findings establish MT‐high T cells as promising biomarkers for identifying individuals at risk for COPD and as novel targets for future therapeutic and prophylactic strategies.
- 13 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (22) , e09332
Open AccessSingle‐Cell RNA Sequencing of Human Lung Tissues Reveals Metallothionein‐Positive T Cells as a Novel Potential Marker of Susceptibility to Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous disease with complex pathogenesis. Identifying high‐risk populations and implementing timely prevention strategies are critical to reducing the disease burden. Single‐cell RNA sequencing of lung tissue from control never‐smokers, patients with pre‐COPD, and COPD patients revealed a novel T cell subset characterized by high expression of metallothionein (MT) genes, designated MT‐high T cells. These cells were progressively depleted in the lungs with disease progression. A similar decline was observed in the peripheral blood using flow cytometry, highlighting the potential of these cells to serve as an accessible biomarker of disease progression. Functional analysis indicated that MT‐high T cells suppress CD8 + T cell cytotoxic activity, suggesting a key immunoregulatory role in disease pathogenesis. Receiver operating characteristic curve analysis demonstrated the excellent potential of MT‐high T cell frequency to predict susceptibility to COPD. These findings establish MT‐high T cells as promising biomarkers for identifying individuals at risk for COPD and as novel targets for future therapeutic and prophylactic strategies.
- 6 August 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
SPP1 Regulates Alveolar Type 2 Cell-Macrophage Crosstalk and Epithelial Cell Fate in Iron-Driven Lung Fibrosis
Pulmonary fibrosis, a life-threatening respiratory condition affecting millions globally, is characterized by progressive lung scarring that severely compromises respiratory function. With few effective treatment options available, it carries a poor prognosis for those affected. Disrupted iron homeostasis is increasingly implicated in its pathogenesis, yet the precise mechanisms linking iron overload to fibrotic progression remain elusive. This study unveils a novel pathway by which iron accumulation orchestrates fibrotic remodeling via secreted phosphoprotein 1 (SPP1)-mediated reprogramming of alveolar type 2 (AT2) cells. Using an integrated approach combining analysis of public single-cell and single-nucleus RNA sequencing datasets with functional validation across multiple murine models of pulmonary fibrosis (iron-induced, bleomycin-induced, and silica-induced), we demonstrate that iron overload within AT2 cells triggers a coordinated transcriptional cascade affecting iron handling, immune cell recruitment, and cellular differentiation. Mechanistically, SPP1 emerges as a key mediator, functioning both externally as a paracrine signal for macrophage recruitment following iron-induced secretion from AT2 cells, and internally as a driver of pathological epithelial transitions, specifically fostering the development of a Krt8+ alveolar intermediate phenotype. The clinical relevance of these findings is substantiated by analysis of human idiopathic pulmonary fibrosis specimens using publicly available single-cell and spatial transcriptomic datasets. These analyses reveal conserved pathway activation and a distinctive spatial organization of SPP1-expressing AT2 cells within remodeled tissue microenvironments, notably in close proximity to macrophages. By establishing SPP1 as a critical nexus between iron dysregulation and fibrotic progression, our work identifies the SPP1 signaling axis as a compelling therapeutic target for this devastating condition.
- 6 August 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
SPP1 Regulates Alveolar Type 2 Cell-Macrophage Crosstalk and Epithelial Cell Fate in Iron-Driven Lung Fibrosis
Pulmonary fibrosis, a life-threatening respiratory condition affecting millions globally, is characterized by progressive lung scarring that severely compromises respiratory function. With few effective treatment options available, it carries a poor prognosis for those affected. Disrupted iron homeostasis is increasingly implicated in its pathogenesis, yet the precise mechanisms linking iron overload to fibrotic progression remain elusive. This study unveils a novel pathway by which iron accumulation orchestrates fibrotic remodeling via secreted phosphoprotein 1 (SPP1)-mediated reprogramming of alveolar type 2 (AT2) cells. Using an integrated approach combining analysis of public single-cell and single-nucleus RNA sequencing datasets with functional validation across multiple murine models of pulmonary fibrosis (iron-induced, bleomycin-induced, and silica-induced), we demonstrate that iron overload within AT2 cells triggers a coordinated transcriptional cascade affecting iron handling, immune cell recruitment, and cellular differentiation. Mechanistically, SPP1 emerges as a key mediator, functioning both externally as a paracrine signal for macrophage recruitment following iron-induced secretion from AT2 cells, and internally as a driver of pathological epithelial transitions, specifically fostering the development of a Krt8+ alveolar intermediate phenotype. The clinical relevance of these findings is substantiated by analysis of human idiopathic pulmonary fibrosis specimens using publicly available single-cell and spatial transcriptomic datasets. These analyses reveal conserved pathway activation and a distinctive spatial organization of SPP1-expressing AT2 cells within remodeled tissue microenvironments, notably in close proximity to macrophages. By establishing SPP1 as a critical nexus between iron dysregulation and fibrotic progression, our work identifies the SPP1 signaling axis as a compelling therapeutic target for this devastating condition.
- 1 May 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (5) , C1487-C1500
A novel lncRNA ABCE1-5 regulates pulmonary fibrosis by targeting KRT14
In the present study, our data first reveal that a novel lncRNA ABCE1-5 could inhibit pulmonary fibrosis through interacting with krt14 and negative regulation of its expression, and indicated ABCE1-5 also regulates the phosphorylation of mTOR and Akt, thus acting on extracellular matrix remodeling in lung fibrosis procession. These results suggest that novel molecules within the ABCE1-5-krt14-mTOR axis may serve as potential candidates for clinical application in IPF.
- 1 May 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (5) , C1487-C1500
A novel lncRNA ABCE1-5 regulates pulmonary fibrosis by targeting KRT14
In the present study, our data first reveal that a novel lncRNA ABCE1-5 could inhibit pulmonary fibrosis through interacting with krt14 and negative regulation of its expression, and indicated ABCE1-5 also regulates the phosphorylation of mTOR and Akt, thus acting on extracellular matrix remodeling in lung fibrosis procession. These results suggest that novel molecules within the ABCE1-5-krt14-mTOR axis may serve as potential candidates for clinical application in IPF.
- Open Access
- 19 March 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (8) , 988-990
Characteristics of untargeted metabolomics of common bacterial pathogens in respiratory diseases
- 19 March 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (8) , 988-990
Open AccessCharacteristics of untargeted metabolomics of common bacterial pathogens in respiratory diseases
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 327 (4) , C979-C993
Iron-laden macrophage-mediated paracrine profibrotic signaling induces lung fibroblast activation
This study investigates the role of iron in pulmonary fibrosis, specifically focusing on macrophage-mediated mechanisms. Iron accumulation in fibrotic lung macrophages triggers lipid peroxidation and an upregulation of transforming growth factor (TGF)-β1 expression. Coculturing iron-laden macrophages activates lung fibroblasts in a TGF-β1-dependent manner, which can be mitigated by ferroptosis inhibitors. These findings underscore the potential of targeting iron overload and lipid peroxidation as a promising strategy to alleviate fibrotic stimulation provoked by disease-associated macrophages.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 327 (4) , C979-C993
Iron-laden macrophage-mediated paracrine profibrotic signaling induces lung fibroblast activation
This study investigates the role of iron in pulmonary fibrosis, specifically focusing on macrophage-mediated mechanisms. Iron accumulation in fibrotic lung macrophages triggers lipid peroxidation and an upregulation of transforming growth factor (TGF)-β1 expression. Coculturing iron-laden macrophages activates lung fibroblasts in a TGF-β1-dependent manner, which can be mitigated by ferroptosis inhibitors. These findings underscore the potential of targeting iron overload and lipid peroxidation as a promising strategy to alleviate fibrotic stimulation provoked by disease-associated macrophages.
- Open Access
- 20 August 2024
- Published by Springer Nature in Lung
- Vol. 202 (5) , 487-499
The Lymphatic Highway: How Lymphatics Drive Lung Health and Disease
The pulmonary lymphatic system has emerged as a critical regulator of lung homeostasis and a key contributor to the pathogenesis of respiratory diseases. As the primary conduit responsible for maintaining fluid balance and facilitating immune cell trafficking, the integrity of lymphatic vessels is essential for preserving normal pulmonary structure and function. Lymphatic abnormalities manifest across a broad spectrum of pulmonary disorders, underscoring their significance in respiratory health and disease. This review provides an overview of pulmonary lymphatic biology and delves into the involvement of lymphatics in four major lung diseases: chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), asthma, and lung transplant rejection. We examine how lymphatic abnormalities manifest in each of these conditions and investigate the mechanisms through which lymphatic remodeling and dysfunction contribute to disease progression. Furthermore, we explore the therapeutic potential of targeting the lymphatic system to ameliorate these debilitating respiratory conditions. Despite the current knowledge, several crucial questions remain unanswered, such as the spatial and temporal dynamics of lymphatic changes, the molecular crosstalk between lymphatics and the lung microenvironment, and the distinction between protective versus detrimental lymphatic phenotypes. Unraveling these mysteries holds the promise of identifying novel molecular regulators, characterizing lymphatic endothelial phenotypes, and uncovering bioactive mediators. By harnessing this knowledge, we can pave the way for the development of innovative disease-modifying therapies targeting the lymphatic highway in lung disorders.
- 20 August 2024
- Published by Springer Nature in Lung
- Vol. 202 (5) , 487-499
Open AccessThe Lymphatic Highway: How Lymphatics Drive Lung Health and Disease
The pulmonary lymphatic system has emerged as a critical regulator of lung homeostasis and a key contributor to the pathogenesis of respiratory diseases. As the primary conduit responsible for maintaining fluid balance and facilitating immune cell trafficking, the integrity of lymphatic vessels is essential for preserving normal pulmonary structure and function. Lymphatic abnormalities manifest across a broad spectrum of pulmonary disorders, underscoring their significance in respiratory health and disease. This review provides an overview of pulmonary lymphatic biology and delves into the involvement of lymphatics in four major lung diseases: chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), asthma, and lung transplant rejection. We examine how lymphatic abnormalities manifest in each of these conditions and investigate the mechanisms through which lymphatic remodeling and dysfunction contribute to disease progression. Furthermore, we explore the therapeutic potential of targeting the lymphatic system to ameliorate these debilitating respiratory conditions. Despite the current knowledge, several crucial questions remain unanswered, such as the spatial and temporal dynamics of lymphatic changes, the molecular crosstalk between lymphatics and the lung microenvironment, and the distinction between protective versus detrimental lymphatic phenotypes. Unraveling these mysteries holds the promise of identifying novel molecular regulators, characterizing lymphatic endothelial phenotypes, and uncovering bioactive mediators. By harnessing this knowledge, we can pave the way for the development of innovative disease-modifying therapies targeting the lymphatic highway in lung disorders.
- Open Access
- 9 April 2024
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 21 (1) , 2322605
Imbalanced and Unchecked: The Role of Metal Dyshomeostasis in Driving COPD Progression
Chronic obstructive pulmonary disease (COPD) stands as a prominent global cause of morbidity and mortality, predicted to rank as the third leading cause of death by 2030 [1–3]. Encompassing emphyse...
- 9 April 2024
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 21 (1) , 2322605
Open AccessImbalanced and Unchecked: The Role of Metal Dyshomeostasis in Driving COPD Progression
Chronic obstructive pulmonary disease (COPD) stands as a prominent global cause of morbidity and mortality, predicted to rank as the third leading cause of death by 2030 [1–3]. Encompassing emphyse...